CompletedPhase 4

Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

Czechia161 participantsStarted 2021-04-01

Plain-language summary

A non-inferiority, open-label, multicentre randomised controlled trial to compare two therapeutic regimens for the treatment of uncomplicated urogenital, rectal or pharyngeal gonorrhoea in men and women between 18 and 75 years of age. Patients were enrolled and treated from April 2021 to June 2022 at the Dermatovenerology Department, University Hospital Bulovka, Prague, Czech Republic and the Venereology Prague, Medicentrum Beroun, Prague, Czech Republic.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * uncomplicated urogenital, rectal or pharyngeal gonorrhoea diagnosed using the nucleic acid amplification test Exclusion Criteria: * any antimicrobial treatment during the 4 weeks before study enrolment * pregnancy or lactation * autoimmune disease * renal, hepatic or cardiac insufficiency * immunosuppressive therapy * allergy to cephalosporins, macrolides or doxycycline

What they're measuring

Number of Participants with negative cultures 1 and 3 weeks and a negative NAAT 3 weeks (±3 days) after treatment initiation.

Timeframe: One and three weeks (±3 days)

Trial details

NCT IDNCT06090565

SponsorBulovka Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-30

View on ClinicalTrials.gov More Gonorrhea trials